NasdaqGM:KOD 1 Year Share Price vs Fair Value Explore Kodiak Sciences's Fair Values from the Community and select ...

Barclays raised the firm’s price target on Kodiak Sciences (KOD) to $7 from $4 and keeps an Underweight rating on the shares. The company’s Q2 ...

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that ...

PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended ...

Fintel reports that on August 14, 2025, JP Morgan upgraded their outlook for Kodiak Sciences (NasdaqGM:KOD) from Underweight to Neutral. Analyst Price Forecast Suggests 14.21% Downside As of August ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...

PALO ALTO, Calif. , July 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing ...

PALO ALTO, Calif., Nov. 16, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative ...

Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases.

PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ...

--Kodiak Sciences Inc., today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R ...

--Kodiak Sciences Inc., today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said ...